Experiences with Pulmonary artery sarcoma

This page shows detailed information about a disease such as statistics, patient reviews and related articles.

Also known as:
Pulmonary artery intimal sarcoma
ICD10/11 Code: I28.8
ICD10/11 Group: I00-I99, Diseases of the circulatory system
reviews
Pulmonary artery sarcoma
Also known as: Pulmonary artery intimal sarcoma
ICD10/11 Code: I28.8, ICD10/11 Group: I00-I99, Diseases of the circulatory system

Read our patient's reviews about Pulmonary artery sarcoma

No recent reviews to display.

We are sorry but at the moment we do not have any recent reviews to show you. Contribute to this platform and share your experience with other patients. Choose one of the options below.


Most used drugs for this disease


Reviews from the most used drugs for this disease

Votrient

3/11/2022 | | 57moderated by Henry
Pazopanib (400MG) for Pulmonary artery sarcoma

I started Votrient at 400 mg for pulmonary artery sarcoma. I began at 400 mg as I have another rare disease, Fibromuscular dysplasia, that increases blood pressure so my oncologist started me at 400 mg to be safe. Within two weeks, I broke out in a rash and two weeks later my liver tests showed extremely elevated numbers. My CT showed stability and my dose was lowered to 200 mg. Will conti...
> read full review...

Most reviewed diseases


The content on this page is user-generated content, read and revised before approval to comply with our standards for a condition review or reaction. We do not enforce any proven medical knowledge from our users to allow them to present their experiences. This way, the opinions and experiences described state only the views of the writers and not those of the owner of this website. Remember that these experiences differ from person to person and that you should always contact your doctor or pharmacist for advice on medication.

Copyright © 2008-2024 Insight Pharma Services BV.
All rights reserved.
Most icons from FontAwesome. Some icons made by Prosymbols from www.flaticon.com and licensed as CC 3.0 BY.